News
2h
Zacks Investment Research on MSNLLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III StudyShares of Eli Lilly LLY soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the ...
Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...
Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment ...
Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.
Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...
Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...
A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...
We recently published a list of the 10 Best Long Term Stocks to Buy According to Billionaires. In this article, we are going ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results